Novel solution to facilitate streamlined home based care for cancer patients

提出本申请的申请人已经开发了一种新型的医学诊断技术，其能够使用小型激光器、特殊类型的相机和智能软件的组合来测量来自患者血液样本的非常精确的光学信号。这种非常精确的光学信号或“光学指纹”是一种非常强大的方法，因为它能够在患者的血液中检测出通常非常复杂的疾病。至关重要的是，这种方法是比大多数现有诊断系统的主要优势，大多数现有诊断机器依赖于向血液中添加特定化学物质并通过多个步骤处理血液，以使化学物质能够检测和测量疾病（或生物标志物）感兴趣。添加这些化学物质和运行测试的过程会大大增加现有医疗诊断产品的成本和复杂性。iLoF的诊断技术不需要复杂和昂贵的化学标签或大量的工艺步骤。该技术基于对血液样本的直接测量（即光学指纹），是新一代廉价，方便和有效的血液检测产品的基础。iLoF开发了这种诊断系统的一个版本，以提高诊断痴呆症患者阿尔茨海默病的简易性和简单性。癌症专家已与iLoF接触，他们有兴趣了解iLoF平台是否可用于改善卵巢癌女性的治疗和管理。该平台有可能在办公室，家庭或远程环境中提供非常快速和简单的测试，为医疗保健专业人员和患者提供有关其癌症状态和治疗途径的重要确认。iLoF正在寻求快速启动创新资金，以了解在卵巢癌诊断市场使用该技术的可行性。该项目与快速启动创新竞赛特别相关，因为它将光子学，人工智能，计算，生物信息学结合到一个项目中，使女性能够自我管理卵巢癌并呈现未来的癌症。

The applicants presenting this application have developed a new type of medical diagnostic technology that is able to use a combination of a small laser, special type of camera and intelligent software to measure a very precise optical signal from a patient's blood sample. This very precise optical signal or "optical fingerprint" is a very powerful method as it enables often very complex diseases to be detected in a patient's blood. Crucially, this approach is a major advantage over most existing diagnostic systems, the majority of existing diagnostic machines are reliant on adding specific chemicals to the blood and processing the blood in a number of steps to enable the chemical to detect and measure the disease (or biomarker) of interest. Adding these chemicals and the process of running the test add significant costs and complexity to existing medical diagnostic products.iLoF's diagnostic technology does not require complex and costly chemical labels or lots of process steps. The technology is based on making a direct measurement (i.e. the optical fingerprint) of the blood sample and is the basis for a new generation of cheap, convenient and effective blood testing products.iLoF has developed a version of this diagnostic system to improve the ease and simplicity of diagnosing Alzheimer Disease in people with dementia. This product is in advanced clinical studies at present.iLoF has been approached by cancer specialists, they are interested to understand if the iLoF platform can be used to improve how women with ovarian cancer are treated and managed. The platform has the potential to provide a very quick and simple test in an office, home or remote setting to provide the healthcare professional and patient with important confirmation about the status of their cancer and treatment pathway. iLoF is seeking Fast Start Innovation funding to be able to understand the feasibility of using the technology in the ovarian cancer diagnostic market. This project is particularly relevant to the Fast Start Innovation competition because is combines, photonics, AI, computing, bioinformatics into one project enable women to ovarian cancer to self-manage and present future cancers.